Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: A case report and review of the literature

Oncology Research

Volumn 20, Issue 10, 2013, Pages 483-490

  Galizia, Danilo ^a   Palesandro, Erica ^a   Nuzzo, Anna Maria ^a   Pignochino, Ymera ^a   Aliberti, Sandra ^a   Aglietta, Massimo ^a   Grignani, Giovanni ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Leiomyosarcoma; Lung metastases; Soft tissue sarcoma; Thigh; Trabectedin

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; IODINATED CONTRAST MEDIUM; TRABECTEDIN;

ABDOMINAL PAIN; AGED; ALOPECIA; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; JAUNDICE; KIDNEY FAILURE; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NODULE; MALE; METASTATIC LEIOMYOSARCOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PLATINUM SENSITIVE OVARIAN CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THIGH; THROMBOCYTOPENIA; VOMITING;

EID: 84883031421     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13685487925130     Document Type: Review

References (27)

1. Skubitz, K. M.; D'Adamo, D. R. Sarcoma. Mayo Clin. Proc. 8:1409-1432; 2007.
2. Fauth, C. T.; Bruecks, A. K.; Temple, W.; Arlette, J. P.; DiFrancesco, L. M. Superficial leiomyosarcoma: A clinicopathologic review and update. J. Cutan. Pathol. 37:269-276; 2010.
3. Svarvar, C.; Böhling, T.; Berlin, O.; Gustafson, P.; Follerås, G.; Bjerkehagen, B.; Domanski, H. A.; Sundby Hall, K.; Tukiainen, E.; Blomqvist, C. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer 109:282-291; 2007.
4. Collins, I. M.; Thomas, D. M. Novel approaches to treatment of leiomyosarcomas. Curr. Oncol. Rep. 13:316-322; 2011.
5. Scurr, M. Histology-driven chemotherapy in soft tissue sarcomas. Curr. Treat. Options Oncol. 12:32-45; 2011.
6. Van Glabbeke, M.; van Oosterom, A. T.; Oosterhuis, J. W.; Mouridsen, H.; Crowther, D.; Somers, R.; Verweij, J.; Santoro, A.; Buesa, J.; Tursz, T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracyclinecontaining first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone. J. Clin. Oncol. 17:150-157; 1999.
7. Maki, R. G.; Wathen, J. K.; Patel, S. R.; Priebat, D. A.; Okuno, S. H.; Samuels, B.; Fanucchi, M.; Harmon, D. C.; Schuetze, S. M.; Reinke, D.; Thall, P. F.; Benjamin, R. S.; Baker, L. H.; Hensley, M. L. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of Sarcoma Alliance for Research through Collaboration Study 002. J. Clin. Oncol. 25:2755-2763; 2007
8. van der Graaf, W. T.; Blay, J. Y.; Chawla, S. P.; Kim, D. W.; Bui-Nguyen, B.; Casali, P. G.; Schöffski, P.; Aglietta, M.; Staddon, A. P.; Beppu, Y.; Le Cesne, A.; Gelderblom, H.; Judson, I. R.; Araki, N.; Ouali, M.; Marreaud, S.; Hodge, R.; Dewji, M. R.; Coens, C.; Demetri, G. D.; Fletcher, C. D.; Dei Tos, A. P.; Hohenberger, P.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 19:1879-1886; 2012
9. Carter, N. J.; Keam, S. J. Trabectedin: A review of its use in soft tissue sarcoma and ovarian cancer. Drugs 70:355-376; 2010.
10. D'Incalci, M.; Galmarini, C. M. A review of trabectedin (ET-743): A unique mechanism of action. Mol. Cancer Ther. 9:2157-2163; 2010.
11. Thariat, J.; Etienne-Grimaldi, M. C.; Launay-Vacher, V.; Soto-Matos, A.; Fernandez-Teruel, C.; Ghafari, T.; Marcy, P. Y.; Milano, G.; Renée, N.; Gastaud, L.; Thyss, A. Pharmacokinetics of trabectedin on hemodialysis: An application for the management of cancer patients with end-stage renal disease. Cancer Chemother. Pharmacol. 68:1363-1367; 2011.
12. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:205-216; 2000.
13. Germano, G.; Frapolli, R.; Simone, M.; Tavecchio, M.; Erba, E.; Pesce, S.; Pasqualini, F.; Grosso, F.; Sanfilippo, R.; Casali, P. G.; Gronchi, A.; Virdis, E.; Tarantino, E.; Pilotti, S.; Greco, A.; Nebuloni, M.; Galmarini, C. M.; Tercero, J. C.; Mantovani, A.; D'Incalci, M.; Allavena, P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70:2235-2244; 2010.
14. Schöffski, P.; Taron, M.; Jimeno, J.; Grosso, F.; Sanfilippo, R.; Casali, P. G.; Le Cesne, A.; Jones, R. L.; Blay, J. Y.; Poveda, A.; Maki, R. G.; Nieto, A.; Tercero, J. C.; Rosell, R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur. J. Cancer 47:1006-1012; 2011.
15. Xing, D.; Scangas, G.; Nitta, M.; He, L.; Xu, X.; Ioffe, Y. J. M.; Aspuria, P. J.; Hedvat, C. Y.; Anderson, M. L.; Oliva, E.; Karlan, B. Y.; Mohapatra, G.; Orsulic, S. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res. 69:8231-8235; 2009.
16. Sanfilippo, R.; Grosso, F.; Jones, R. L.; Banerjee, S.; Pilotti, S.; D'Incalci, M.; Dei Tos, A. P.; Raspagliesi, F.; Judson, I.; Casali, P. G. Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecol. Oncol. 123:553-556; 2011.
17. Monk, B. J.; Blessing, J. A.; Street, D. G.; Muller, C. Y.; Burke, J. J.; Hensley, M. L. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol. Oncol. 124:48-52; 2012.
18. Demetri, G. D.; Chawla, S. P.; von Mehren, M.; Ritch, P.; Baker, L. H.; Blay, J. Y.; Hande, K. R.; Keohan, M. L.; Samuels, B. L.; Schuetze, S.; Lebedinsky, C.; Elsayed, Y. A.; Izquierdo, M. A.; Gómez, J.; Park, Y. C.; Le Cesne, A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27:4188-4196; 2009.
19. Chawla, S.; Blay, J. Y.; Schuetze, S. Efficacy of secondline trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despit prior conventional chemotherapy [abstract 9427]. Eur. J. Cancer 7(Suppl. 2): 598; 2009.
20. Le Cesne, A.; Gianni, L.; Maki, R. Translocation-related sarcomas (TRS): A retrospective analysis of activity with trabectedin [abstract 9401]. Eur J. Cancer 7(Suppl. 2):590; 2009.
21. Demetri, G.; Blay, J. Y.; Yovine, A. Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are indpendent of patient age [abstract 9402]. Eur. J. Cancer 7(Suppl. 2):590; 2009.
22. Mertens, F.; Antonescu, C. R.; Hohenberger, P.; Ladanyi, M.; Modena, P.; D'Incalci, M.; Casali, P. G.; Aglietta, M.; Alvegård, T. Translocation-related sarcomas. Semin. Oncol. 36:312-323; 2009.
23. Grosso, F.; Jones, R. L.; Demetri, G. D.; Judson, I. R.; Blay, J. Y.; Le Cesne, A.; Sanfilippo, R.; Casieri, P.; Collini, P.; Dileo, P.; Spreafico, C.; Stacchiotti, S.; Tamborini, E.; Tercero, J. C.; Jimeno, J.; D'Incalci, M.; Gronchi, A.; Fletcher, J. A.; Pilotti, S.; Casali, P. G. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol. 8:595-602; 2007.
24. Grosso, F.; D'Incalci, M.; Cartoafa, M.; Nieto, A.; Fernández- Teruel, C.; Alfaro, V.; Lardelli, P.; Roy, E.; Gómez, J.; Kahatt, C.; Soto-Matos, A.; Judson, I. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother. Pharmacol. 69:1557-1565; 2012
25. Casali, P. G.; Sanfilippo, R.; D'Incalci, M. Trabectedin therapy for sarcomas. Curr. Opin. Oncol. 22:342-346; 2010.
26. Grosso, F.; Dileo, P.; Sanfilippo, R.; Stacchiotti, S.; Bertulli, R.; Piovesan, C.; Jimeno, J.; D'Incalci, M.; Gescher, A.; Casali, P. G. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer 42:1484-1490; 2006.
27. Lebedinsky, C.; Gómez, J.; Park, Y. C.; Nieto, A.; Soto-Matos, A.; Parekh, T.; Alfaro, V.; Roy, E.; Lardelli, P.; Kahatt, C. Trabectedin has a low cardiac risk profile: A comprehensive cardiac safety analysis. Cancer Chemother. Pharmacol. 68:1223-1231; 2011.